Dubinsky MC - Search Results

1

Thioguanine: a potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprine.

Dubinsky MC, Feldman EJ, Abreu MT, Targan SR, Vasiliauskas EA. Dubinsky MC, et al. Am J Gastroenterol. 2003 May;98(5):1058-63. doi: 10.1111/j.1572-0241.2003.07413.x. Am J Gastroenterol. 2003. PMID: 12809828

2

Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease.

Ruemmele FM, Targan SR, Levy G, Dubinsky M, Braun J, Seidman EG. Ruemmele FM, et al. Gastroenterology. 1998 Oct;115(4):822-9. doi: 10.1016/s0016-5085(98)70252-5. Gastroenterology. 1998. PMID: 9753483

3

Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease.

Dubinsky MC, Lamothe S, Yang HY, Targan SR, Sinnett D, Théorêt Y, Seidman EG. Dubinsky MC, et al. Gastroenterology. 2000 Apr;118(4):705-13. doi: 10.1016/s0016-5085(00)70140-5. Gastroenterology. 2000. PMID: 10734022 Clinical Trial.

4

Clinical utility of serodiagnostic testing in suspected pediatric inflammatory bowel disease.

Dubinsky MC, Ofman JJ, Urman M, Targan SR, Seidman EG. Dubinsky MC, et al. Am J Gastroenterol. 2001 Mar;96(3):758-65. doi: 10.1111/j.1572-0241.2001.03618.x. Am J Gastroenterol. 2001. PMID: 11280547

5

An open-label pilot study using thioguanine as a therapeutic alternative in Crohn's disease patients resistant to 6-mercaptopurine therapy.

Dubinsky MC, Hassard PV, Seidman EG, Kam LY, Abreu MT, Targan SR, Vasiliauskas EA. Dubinsky MC, et al. Inflamm Bowel Dis. 2001 Aug;7(3):181-9. doi: 10.1097/00054725-200108000-00001. Inflamm Bowel Dis. 2001. PMID: 11515842 Clinical Trial.

6

6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease.

Dubinsky MC, Yang H, Hassard PV, Seidman EG, Kam LY, Abreu MT, Targan SR, Vasiliauskas EA. Dubinsky MC, et al. Gastroenterology. 2002 Apr;122(4):904-15. doi: 10.1053/gast.2002.32420. Gastroenterology. 2002. PMID: 11910342 Clinical Trial.

7

Suspected inflammatory bowel disease--the clinical and economic impact of competing diagnostic strategies.

Dubinsky MC, Johanson JF, Seidman EG, Ofman JJ. Dubinsky MC, et al. Am J Gastroenterol. 2002 Sep;97(9):2333-42. doi: 10.1111/j.1572-0241.2002.05988.x. Am J Gastroenterol. 2002. PMID: 12358253

8

6-thioguanine can cause serious liver injury in inflammatory bowel disease patients.

Dubinsky MC, Vasiliauskas EA, Singh H, Abreu MT, Papadakis KA, Tran T, Martin P, Vierling JM, Geller SA, Targan SR, Poordad FF. Dubinsky MC, et al. Gastroenterology. 2003 Aug;125(2):298-303. doi: 10.1016/s0016-5085(03)00938-7. Gastroenterology. 2003. PMID: 12891528

9

Optimizing immunomodulator therapy for inflammatory bowel disease.

Dubinsky MC. Dubinsky MC. Curr Gastroenterol Rep. 2003 Dec;5(6):506-11. doi: 10.1007/s11894-003-0041-7. Curr Gastroenterol Rep. 2003. PMID: 14602061 Review.

10

Monitoring of AZA/6-MP treatment in children with IBD is necessary.

Dubinsky MC. Dubinsky MC. Inflamm Bowel Dis. 2003 Nov;9(6):386-8; discussion 392-3. doi: 10.1097/00054725-200311000-00007. Inflamm Bowel Dis. 2003. PMID: 14671488 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

402 results

Search Page

Filters